Genmab — Juni 2019
-
New Approaches Target Overcoming Resistance to TKIs in EGFR+ NSCLC https://www.targetedonc.com/news/new-approaches-target-overcoming-resistance-to-tkis-in-egfr-nsclc
-
well, US stiger fint, det hjalp heller ikke
-
Ikke helt ny, men jeg har ikke set den før: Clinical Cancer Research (april 2019):Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL).Citat: our data demonstrate the anti-tumor mechanisms of daratumumab in CLL; furthermore, we show how co-targeting BTK and CD38 lead to a robust anti-CLL effect, which has clinical implications.
-
Jeg ved na´da..:-D
-
Tjaaah.... Er det nu på tredje år at vi sidder og snakker om nu skal vi lige have overstået et eller andet, og derefter vil vi bare se stigning på stigning, vel at mærke med frygt for at Genmab skulle blive solgt for 2000 til 3000 pr. aktie.....Og hvis de da bare ikke var så klodsede i deres udmeldinger. Så havde det også set helt anderledes ud....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind